Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1

ACS Chemical Biology

Volumn 7, Issue 12, 2012, Pages 1984-1993

  Childs Disney, Jessica L ^a   Parkesh, Raman ^a   Nakamori, Masayuki ^b   Thornton, Charles A ^b   Disney, Matthew D ^a  

^a Scripps Florida ^*  (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; MESSENGER RNA PRECURSOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; MYOTONIC DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; RNA SPLICING;

AMINOGLYCOSIDES; ANIMALS; BASE SEQUENCE; DNA PRIMERS; FLUORESCENCE RESONANCE ENERGY TRANSFER; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MYOTONIC DYSTROPHY; POLYMERASE CHAIN REACTION; RNA; RNA SPLICING;

EID: 84871602513     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb3001606     Document Type: Article

References (48)

1. Poehlsgaard, J. and Douthwaite, S. (2005) The bacterial ribosome as a target for antibiotics Nat. Rev. Microbiol. 3, 870-881
2. Thomas, J. R. and Hergenrother, P. J. (2008) Targeting RNA with small molecules Chem. Rev. 108, 1171-1224
3. Guan, L. and Disney, M. D. (2012) Recent Advances in Developing Small Molecules Targeting RNA ACS Chem. Biol. 7, 73-86
4. Alvarez-Salas, L. M. (2008) Nucleic acids as therapeutic agents Curr. Top. Med. Chem. 8, 1379-1404
5. Iorns, E., Lord, C. J., Turner, N., and Ashworth, A. (2007) Utilizing RNA interference to enhance cancer drug discovery Nat. Rev. Drug Discovery 6, 556-568
6. Nesterova, M. and Cho-Chung, Y. S. (2004) Killing the messenger: antisense DNA and siRNA Curr. Drug Targets 5, 683-689
7. Boggs, R. T., McGraw, K., Condon, T., Flournoy, S., Villiet, P., Bennett, C. F., and Monia, B. P. (1997) Characterization and modulation of immune stimulation by modified oligonucleotides Antisense Nucleic Acid Drug Dev. 7, 461-471
8. Farman, C. A. and Kornbrust, D. J. (2003) Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications Toxicol. Pathol. 31 (Suppl.) 119-122
9. Childs-Disney, J. L., Wu, M., Pushechnikov, A., Aminova, O., and Disney, M. D. (2007) A small molecule microarray platform to select RNA internal loop-ligand interactions ACS Chem. Biol. 2, 745-754
10. Disney, M. D., Labuda, L. P., Paul, D. J., Poplawski, S. G., Pushechnikov, A., Tran, T., Velagapudi, S. P., Wu, M., and Childs-Disney, J. L. (2008) Two-dimensional combinatorial screening identifies specific aminoglycoside-RNA internal loop partners J. Am. Chem. Soc. 130, 11185-11194
11. Velagapudi, S. P., Seedhouse, S. J., French, J., and Disney, M. D. (2011) Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis J. Am. Chem. Soc. 133, 10111-10118
12. Disney, M. D. and Childs-Disney, J. L. (2007) Using selection to identify and chemical microarray to study the RNA internal loops recognized by 6′- N -acylated kanamycin A ChemBioChem 8, 649-656
13. Lee, M. M., Pushechnikov, A., and Disney, M. D. (2009) Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2 ACS Chem. Biol. 4, 345-355
14. Pushechnikov, A., Lee, M. M., Childs-Disney, J. L., Sobczak, K., French, J. M., Thornton, C. A., and Disney, M. D. (2009) Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3 J. Am. Chem. Soc. 131, 9767-9779
15. Lee, M. M., Childs-Disney, J. L., Pushechnikov, A., French, J. M., Sobczak, K., Thornton, C. A., and Disney, M. D. (2009) Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy J. Am. Chem. Soc. 131, 17464-17472
16. Disney, M. D., Lee, M. M., Pushechnikov, A., and Childs-Disney, J. L. (2010) The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies ChemBioChem 11, 375-382
17. Liquori, C. L., Ricker, K., Moseley, M. L., Jacobsen, J. F., Kress, W., Naylor, S. L., Day, J. W., and Ranum, L. P. (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9 Science 293, 864-867
18. Savkur, R. S., Philips, A. V., Cooper, T. A., Dalton, J. C., Moseley, M. L., Ranum, L. P., and Day, J. W. (2004) Insulin receptor splicing alteration in myotonic dystrophy type 2 Am. J. Hum. Genet. 74, 1309-1313
19. Faustino, N. A. and Cooper, T. A. (2003) Pre-mRNA splicing and human disease Genes Dev. 17, 419-437
20. Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M., and Thornton, C. A. (2000) Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat Science 289, 1769-1773
21. Philips, A. V., Timchenko, L. T., and Cooper, T. A. (1998) Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy Science 280, 737-741
22. Goun, E. A., Shinde, R., Dehnert, K. W., Adams-Bond, A., Wender, P. A., Contag, C. H., and Franc, B. L. (2006) Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation Bioconjugate Chem. 17, 787-796
23. Goun, E. A., Pillow, T. H., Jones, L. R., Rothbard, J. B., and Wender, P. A. (2006) Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging ChemBioChem 7, 1497-1515
24. Luedtke, N. W., Carmichael, P., and Tor, Y. (2003) Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine J. Am. Chem. Soc. 125, 12374-12375
25. Frankel, A. D. and Pabo, C. O. (1988) Cellular uptake of the tat protein from human immunodeficiency virus Cell 55, 1189-1193
26. Cardani, R., Mancinelli, E., Rotondo, G., Sansone, V., and Meola, G. (2006) Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2 Eur. J. Histochem. 50, 177-182
27. Mastroyiannopoulos, N. P., Feldman, M. L., Uney, J. B., Mahadevan, M. S., and Phylactou, L. A. (2005) Woodchuck post-transcriptional element induces nuclear export of myotonic dystrophy 3′ untranslated region transcripts EMBO Rep. 6, 458-463
28. Amack, J. D., Paguio, A. P., and Mahadevan, M. S. (1999) Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model Hum. Mol. Genet. 8, 1975-1984
29. Jiang, H., Mankodi, A., Swanson, M. S., Moxley, R. T., and Thornton, C. A. (2004) Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons Hum. Mol. Genet. 13, 3079-3088
30. Wojciechowska, M. and Krzyzosiak, W. J. (2011) Cellular toxicity of expanded RNA repeats: focus on RNA foci Hum. Mol. Genet. 20, 3811-3821
31. Childs-Disney, J. L., Hoskins, J., Rzuczek, S., Thornton, C., and Disney, M. D. (2012) Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive ACS Chem. Biol. 7, 856-862
32. Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A., and Berglund, J. A. (2009) Pentamidine reverses the splicing defects associated with myotonic dystrophy Proc. Natl. Acad. Sci. U.S.A. 106, 18551-18556
33. Lee, M. M., French, J. M., and Disney, M. D. (2011) Influencing uptake and localization of aminoglycoside-functionalized peptoids Mol. BioSyst. 7, 2441-2451
34. Koepsell, H., Lips, K., and Volk, C. (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications Pharm. Res. 24, 1227-1251
35. Fuchs, S. M. and Raines, R. T. (2004) Pathway for polyarginine entry into mammalian cells Biochemistry 43, 2438-2444
36. Iozzo, R. V. (1998) Matrix proteoglycans: from molecular design to cellular function Annu. Rev. Biochem. 67, 609-652
37. Mammen, M., Choi, S. K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors Angew. Chem., Int. Ed. 37, 2755-2794
38. Ho, T. H., Charlet, B. N., Poulos, M. G., Singh, G., Swanson, M. S., and Cooper, T. A. (2004) Muscleblind proteins regulate alternative splicing EMBO J. 23, 3103-3112
39. Nezu, Y., Kino, Y., Sasagawa, N., Nishino, I., and Ishiura, S. (2007) Expression of MBNL and CELF mRNA transcripts in muscles with myotonic dystrophy Neuromuscul. Disord. 17, 306-312
40. Warf, M. B. and Berglund, J. A. (2007) MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T RNA 13, 2238-2251
41. Mankodi, A., Takahashi, M. P., Jiang, H., Beck, C. L., Bowers, W. J., Moxley, R. T., Cannon, S. C., and Thornton, C. A. (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy Mol. Cell 10, 35-44
42. Charlet, B. N., Savkur, R. S., Singh, G., Philips, A. V., Grice, E. A., and Cooper, T. A. (2002) Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing Mol. Cell 10, 45-53
43. 2+-ATPase in myotonic dystrophy type 1 Hum. Mol. Genet. 14, 2189-2200
44. Lin, X., Miller, J. W., Mankodi, A., Kanadia, R. N., Yuan, Y., Moxley, R. T., Swanson, M. S., and Thornton, C. A. (2006) Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy Hum. Mol. Genet. 15, 2087-2097
45. Parkesh, R., Childs-Disney, J. L., Nakamori, M., Kumar, A., Wang, E., Wang, T., Hoskins, J., Housman, D. E., Thornton, C. A., Disney, M. D., and Tran, T. (2012) Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database & chemical similarity searching J. Am. Chem. Soc. 134, 4731-4742
46. Chen, C. Z., Sobczak, K., Hoskins, J., Southall, N., Marugan, J. J., Zheng, W., Thornton, C. A., and Austin, C. P. (2012) Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1 Anal. Bioanal. Chem. 402, 1889-1898
47. Cantor, C. R. and Schimmel, P. R. (1980) Biophysical Chemistry, W.H. Freeman and Company, San Francisco.
48. McGhee, J. D. and Hippel, P. H. V. (1974) Theoretical aspects of DNA-protein interactions: cooperative and non-cooperative binding of large ligands to a one-dimensional homogeneous lattice J. Mol. Biol. 86, 469-489